TFF Pharmaceuticals, Inc. and Augmenta Bioworks, Inc. Enter Into a Worldwide Joint Development Agreement for COVID-19 Monoclonal Antibody Therapies

AUSTIN, Texas & MENLO PARK, Calif.--(BUSINESS WIRE)--TFF Pharmaceuticals and Augmenta Bioworks enter into a worldwide joint development agreement for COVID-19 monoclonal antibody therapies.

Click to view original post